XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.3
SHARE OPTION PLANS AND ESPP (Tables)
 9 Months Ended
Sep. 30, 2025
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of stock option plans
A summary of the status of the Company’s option plans as of September 30, 2025 and changes during the period then ended is presented below:
Nine months ended September 30, 2025
Unaudited
Number
of options		Weighted
average
exercise
price
Outstanding at beginning of year11,315,468 $31.41 
Granted944,888 17.96 
Exercised(422,673)14.28 
Forfeited and canceled(843,581)45.34 
Outstanding as of September 30, 202510,994,102 $29.84 
Exercisable options6,997,079 $34.38 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of September 30, 2025 and changes during the period then ended is presented below.
Nine months ended September 30, 2025
Unaudited
Number
of RSU/PSUs		Weighted
average
grant date fair value
Unvested at beginning of year12,066,515 $27.19 
Granted5,444,389 18.62 
Vested(2,899,297)24.59 
Forfeited and cancelled(1,005,508)34.56 
Unvested as of September 30, 2025 (1)13,606,099 23.77 

(1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones that are not probable as of September 30, 2025, in accordance with ASC 718 "Compensation — Stock Compensation" as follows:
 September 30, 2025
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
704,493 $16.30 $11,483 
907,280 18.19 16,503 
21,653 19.44 421 
901,284 48.16 43,406 
73,186 76.97 5,633 
2,607,896 $77,446 
Schedule of fair value assumptions used for all equity based awards estimated using black-scholes option pricing model
The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. The Company assessed fair value using the following underlying assumptions: 
Nine months ended September 30,Year ended December 31,
2024
20252024
UnauditedAudited
Stock Option Plans
Expected term (years)
5.50-5.79
5.50-5.73
5.50-5.73
Expected volatility
75%-77%
71%-73%
71%-73%
Risk-free interest rate
4.01%-4.02%
3.88%-4.43%
3.88%-4.43%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
56%-89%
73%-90%
73%-90%
Risk-free interest rate
4.16%-4.20%
5.13%-5.23%
5.13%-5.23%
Dividend yield0.00 %0.00 %0.00 %
Schedule of non-cash share-based compensation expense related to company's equity-based awards
The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2025 and 2024, and the year ended December 31, 2024 was:
Three months ended September 30,Nine months ended September 30,Year ended December 31,
2024
2025202420252024
UnauditedUnauditedAudited
Cost of revenues$929 $1,834 $3,004 $5,280 $6,873 
Research, development and clinical studies6,166 7,294 18,154 25,421 32,716 
Sales and marketing7,663 10,276 21,538 31,220 43,097 
General and administrative14,563 11,960 42,320 35,357 77,349 
Total share-based compensation expense$29,321 $31,364 $85,016 $97,278 $160,035